|
Drug for post-menopausal women with advanced breast cancer
Post-menopausal women with advanced breast cancer, known to be sensitive to hormonal treatments, can now be offered a drug that is superior to the most commonly used first line treatment. New data from clinical trials, presented at the annual meeting of the American Society of Clinical Oncology in New Orleans (ASCO) indicates that, in this group of patients, treatment with a selective aromatase inhibitor delays progression of their cancer for longer than in those receiving the current gold standard treatment.
|
